Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceritinib in ALK-positive advanced solid tumors
NCT02465528Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, open-label trial of ceritinib in inflammatory myofibroblastic tumor (IMT), anaplastic large cell lymphoma (ALCL), glioblastoma (GBM) and 1 more (4 arms), sponsored by Novartis. Primary endpoint: Disease Control Rate at 16 weeks. Started May 2016; status: terminated.
02
Drugs
ceritinib
03
Conditions
inflammatory myofibroblastic tumor (IMT)anaplastic large cell lymphoma (ALCL)glioblastoma (GBM)solid tumor
Beyond the preview
Go deeper on NCT02465528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465528.